Figure 2
From: MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2
(A) Predicted alignment of miR-184 to the mRNA 3'UTR region of AKT2 , as predicted by the Sanger miR Registry. (B) AKT2 mRNA levels were significantly different (p < 0.002) between tumours with high miR-184 levels (predominantly MNA tumors)(n = 10) and tumours with low miR-184 levels (predominantly non-MNA)(n = 9). AKT2 mRNA levels were also significantly different (p < 0.035) between tumours with MNA (n = 10) versus non-MNA (n = 9).